

10/530340

PATENT  
JC13 R001 PCT/PTO 01 APR 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Robert Y. Tsai  
**Application No.:** To be assigned  
**Filed:** To be assigned  
**Confirmation No.:** To be assigned  
**For:** METHODS FOR CONTROLLING  
PROLIFERATION OF CELLS  
**Examiner:** To be assigned  
**Art Unit:** To be assigned  
**Attorney Reference No.** 4239-66642-05

## CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label No. EV510808475US in an envelope addressed to: MAIL STOP PCT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent  
for Applicant(s)

Date Mailed April 1, 2005

MAIL STOP PCT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 C.F.R. § 1.97(b)(2)**

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language and/or non-English-language documents. Due to its size, a copy of listed reference No. WO 00/05873 is attached hereto on CD-ROM. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this IDS is enclosed.

10/530340


SAS:jam 04/01/2005 4239-42-05

JC1 C'd PCT/PTO <sup>PATENT</sup> 31 APR 2005

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By   
Susan Alpert Siegel, Ph.D.  
Registration No. 43,121

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

cc: Docketing

10/530340  
JC13 P  
PCT/PTO 01 APR 2005

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Attorney Docket Number	4239-66642-05
		Application Number	To be assigned
		Filing Date	To be assigned
		First Named Inventor	Robert Y. Tsai
		Art Unit	To be assigned
		Examiner Name	To be assigned

### U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		US 2003/0008284 A1	09 Jan 2003	Kennedy et al.

### FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO/PCT	WO 00/05873	05 Oct 2000	
		WIPO/PCT	WO 01/40461 A2	07 June 2001	Multigene Biotech GmbH
		WIPO/PCT	WO 01/96523 A2	20 Dec 2001	Chiron Corporation

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		Genseq No. AN AAM48961, Kennedy et al., "Detecting a cancerous colon cell, useful for diagnosing colon cancer and for rational drug and therapy design, comprising detecting at least one differentially expressed gene product," WO 01/196523, 20 December 2001
		Genseq No. AN AAB43305, Shimkets et al., "Novel nucleic acids and peptides derived from open reading frame X, useful for treating e.g. cancers, proliferative disorders, neurodegenerative disorders and cardiovascular disease," WO 00/05873, 05 October 2000
		Genseq No. AN AAB86210, "New nucleic acid encoding interactors of Fanconi anemia protein, useful for diagnosis, treatment and prevention of e.g. DNA-repair defects or cell-cycle disorders," WO 01/140461, 07 June 2001
		GenBank Accession No. AAH01024

EXAMINER SIGNATURE:	DATE CONSIDERED:
---------------------	---------------------

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.